Member Info for crumbs

Not funded by scancell this one but benefiting :)

https://jobs.nottingham.ac.uk/Vacancy.aspx?id=31302&forced=2

Or maybe they didn't fail lol ... I wonder though was this a plan or something that more came to pass due to circumstance

I believe they tried to but failed? Like you I don't know much about it and would also be interested in the story and what their plan there is...

The other thing with SCIB2 coming back and having a scancell funded trial would be - data we would have updates which we would not have got from CRUK and yes the fact it is going to be nano delivered makes it a next-gen ImmunoBody trial... So it is very sad that CRUK is suffering as they do a great deal of important work and Lindy has certainly benefited from their funding over the years but having SCIB2 back is not so bad now we can afford to run our own trial...

Redmile indeed do know much more than us and you have to presume they are liking what they hear about moditope, I would expect they have a good relationship with Sahin and would have had 'conversations' .... I saw no mention of TCR in the RNS...
what their end game is is what I guess concerns us most.... Boom I believe? said they only like to be inested for short time periods... Let us hope we all go along for the ride to ends of maximum value together :)

It might well be scancell have told they can or been asked by the potential partner to prove something up with more data... scancell only got the CRUK deal on SCIB2 after doing the preclincal with it combined with a CI.....

Ir would be the better conclusion lol

Certainly, I share your frustrations douve on the inability to nail that all-important commercial deal... the BioNTech collab had a 6 months delay but they ought to have concluded that one too by now.... you would think redmile would know a lot more about that particular one though.

Antibody-drug Conjugates (ADC) are empowered antibodies (mAbs) designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents. An ideal ADC has:

A highly selective monoclonal antibody (mAb) for a tumor-associated antigen that has restricted or no expression on normal (healthy) cells;
A potent cytotoxic agent (generally a small molecule drug with high systemic toxicity) designed to induce target cell death after being internalized in the tumor cell and released;
A linker that is stable in circulation, but releases the cytotoxic agent in target cells.
Covalently linked monoclonal antibodies to small molecule drugs that target the specific cancer cell to reduce systemic toxicity
Increase the cell-killing potential of monoclonal antibodies (mAbs), and
Confer higher tumor selectivity. As a result, the tolerability of the drug increases.
Compared to standard chemotherapeutic drugs or biologics, there is limited systemic exposure
Mechanistically, antibody-drug conjugates exert their activity by (1) selective binding of the antibody to tumor, (2) internalization and (3) lysosomal degradation, and release of the cytotoxic payload, leading to cytotoxic cell death.

https://www.adcreview.com/the-review/antibody-drug-conjugates/what-are-antibody-drug-conjugates/

possibly the research collab that has finished now has been extended around this? Again something to ask scancell

'· Build on existing antibody expertise to further advance the preclinical development of the TaG antibodies, including as antibody-drug conjugates ("ADC")'

Also we don't really know what added value and how and how long it takes it might be a couple of weeks work it might be months or years who knows... though seems to be something around 'ADC' it could be something that came up in the research collaboration.... the word 'concluding' is interesting too as to me suggests it is not a case of deal we were getting is off...

It will interesting to see the funded progress now of Modi 2

'Clinical significance
NPM1 gene is up-regulated, mutated and chromosomally translocated in many tumor types. Chromosomal aberrations involving NPM1 were found in patients with non-Hodgkin lymphoma, acute promyelocytic leukemia, myelodysplastic syndrome, and acute myelogenous leukemia.[7] Heterozygous mice for NPM1 are vulnerable to tumor development. In solid tumors NPM1 is frequently found overexpressed, and it is thought that NPM1 could promote tumor growth by inactivation of the tumor suppressor p53/ARF pathway; on the contrary, when expressed at low levels, NPM1 could suppress tumor growth by the inhibition of centrosome duplication.

Of high importance is NPM involvement in acute myelogenous leukemia,[8] where a mutated protein lacking a folded C-terminal domain (NPM1c+) has been found in the cytoplasm in patients. This aberrant localization has been linked to the development of the disease, and is associated with improved clinical outcomes. Strategies against this subtype of acute myelogenous leukemia include the refolding of the C-terminal domain using pharmalogical chaperones and the displacement of the protein from nucleolus to nucleoplasm, which has been linked to apoptotic mechanisms. It has also been shown that in the context of clonal hematopoiesis of undetermined significance harboring a DNMT3A mutation, subsequent NPM1 mutations drive progression into overt myeloproliferative neoplasm.[9]'
https://en.wikipedia.org/wiki/NPM1

NASDAQ listing has certainly not done BioNTech any harm! An mcap of over $21 billion and that on no approved commercial products roo....like I say certainly a lot to be discussed at AGM

What I'm hoping is though seems no MaB deals on the way there could be some pharma action on its way possibly around covidity or moditope and this support from redmile is crucial too it... but so far scancell and commercial deals is ..thud!

I have though already put the funds into my account for me OO's :)

With SCIB2 we are led to believe from CH's proactive answers that the delivery method- nano was what was taking time there and that that is now sorted and indeed the delivery tech has been 'licensed' ... which to me seemed to mean CRUK had licensed it but till we know dunno... SCIB2 has indeed turned into as frustrating a saga as SCIB1....
One thing is for sure lots and lots need to be asked and found out at AGM

I'm also not over the moon with today's news.... though obviously that redmile have taken such a shine to and funded scancell enough to get the company much further and hopefully reach full value is a positive if it indeed plays out like that for us pi

I very much doubt they are going down the CAR T road as it were but they are hiring a CAR T specialist and we think most probably to do work around the CAR T potential of the MaBs.... something must have triggered this wether it is something that has come from the 3 research collabs or some other thing that must have got team science scancell wanting to do more of their own work on the MaBs... there is a lot of potential there again the only thing I can think that has put scancell off concluding what looked (at least as much as we were told) like a certain deal on them or one of them was they were not happy with the value that was being offered ... Will be good to hear more on this roll on the AGM

Probably the deal amount being offered was not to scancells liking and they must feel doing some more of their own work... probably around the CAR T angle will make them a much more valuable asset.... though unless they tell us we just don't know, whatever the reasons redmile seem to be in agreement

Not likely...

'Avidimab™ platform and the TaG antibodies update

With the additional funds available from the Capital Raise, the Company intends to add further value to both the Avidimab™ platform and the TaG antibodies before concluding any licensing deals.'

I think it may explain the hiring of a CAR T specialist

I don't know has Burble commented on the recruitments or not yet but would be interested in his take on in particular

'Research Scientist 3 (CAR-T cell immunology)

Key responsibilities:

Produce lentiviral CAR constructs, transduce T cells and assess their target killing potential in vitro and in vivo
Critically analyse and interpret data and produce timely reports
Review current literature to direct project progression
Essential skills/requirements:

PhD in immunology, the role would suit a newly qualified PhD level scientist with proven lentiviral/CAR T cell or TCR analysis experience
Evidence of published work in a CAR T cell/TCR-related field
Detailed knowledge of human immunology
Experience with lentiviral transduction/transfection of immune cells
Proficient in immunological assays such as ELISpot, multicolour flow cytometry, CTL lysis
Proficient in sterile cell culture of cell lines and isolation (bead-based) and culture of primary human/mouse cells.
Experience in flow cytometry-based cell sorting'

Is it about the MaBs especially the extra special FG2811.... Or something else?... I certainly do not know we know CAR T/TCR is not an area scancell have gone into alone before as the costs involved are mahoosive which is why TCR is a collab with BioNTech and all their fancy lab gear capabilities ....

Anyways anyones views on this new direction most welcome... we all know it is a very hot area with massive deal/s done around it.

Though indeed not indicative of deal/s imminent though they may be indeed that first glycan one is even to be expected (what a torrid day for knowlesi that would be) but the recruitment shows scancell is growing .... Also intriguingly we may get to hear something around CAR T / TCR as obviously scancell stuff is going on there!.... Lindy still not sleeping!

What a time to buy it was! And I was :)